Bank of America just raised its EUR/USD forecast
BOSTON - Bicara Therapeutics Inc. (NASDAQ:BCAX), a $753 million market cap biopharmaceutical company focused on bifunctional therapies for solid tumors, announced today that it will present updated data from a Phase 1/1b trial of its drug candidate ficerafusp alfa at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. The company’s stock has shown strong momentum with a 17.5% gain over the past week, according to InvestingPro data. The meeting will take place from May 30 to June 3, 2025, in Chicago, IL.
Ficerafusp alfa, a first-in-class bifunctional antibody targeting both EGFR and TGF-β, is currently under investigation for its effectiveness in treating recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The company’s Chief Medical Officer, David Raben, MD, expressed that the selection for an oral presentation at the prestigious ASCO event underscores the clinical community’s interest in the drug’s survival and durability data. InvestingPro analysis shows the company maintains a strong financial health score, with liquid assets significantly exceeding short-term obligations and a healthy cash position relative to debt.
The presentation, scheduled for June 1, 2025, will provide updated results from an expansion cohort of the trial, which includes patients with HPV-negative HNSCC—a group generally facing poorer outcomes compared to HPV-positive patients.
Bicara’s lead program, ficerafusp alfa, aims to inhibit both cancer cell growth and the immunosuppressive environment within tumors, potentially offering a new treatment avenue for HNSCC and other solid tumor types. The company is also conducting a pivotal Phase 2/3 clinical trial named FORTIFI-HN01 in this patient population.
The presentation details, including the abstract number and session information, will be made available on Bicara’s website following the ASCO meeting.
This news is based on a press release statement from Bicara Therapeutics and contains forward-looking statements regarding the clinical development and potential efficacy of ficerafusp alfa. These statements are subject to risks and uncertainties and actual results may differ from those projected. The company cautions that these forward-looking statements are valid only as of today and are not guarantees of future performance. Investors should note that Bicara is scheduled to report its next earnings on May 28, 2025. InvestingPro subscribers have access to 8 additional key insights about BCAX’s financial health and market position.
In other recent news, Bicara Therapeutics Inc has been the focus of several analyst reports and financial updates. H.C. Wainwright adjusted its price target for Bicara from $45 to $44, maintaining a Buy rating, as they anticipate upcoming presentations at the American Association for Cancer Research conference. These presentations are expected to showcase important data on Bicara’s cancer treatments, including ficerafusp alfa studies. Meanwhile, Cantor Fitzgerald maintained an Overweight rating on Bicara, citing a decrease in net loss and better-than-expected earnings per share for the fourth quarter of 2024. Cantor Fitzgerald also revised its research and development spending estimates for 2025, increasing it to $92 million, reflecting the anticipated costs of a phase 3 clinical trial.
Stifel analysts raised Bicara’s stock price target to $48 from $47, reiterating a Buy rating, and highlighted the company’s upcoming data releases in the second quarter of 2025. These releases will include data from monotherapy dose-expansion studies and updated results from a combination study with pembrolizumab. The analysts believe that the forthcoming data will provide more insights into ficerafusp alfa’s efficacy and potential market impact. Additionally, Cantor Fitzgerald expressed optimism about ficerafusp’s competitive positioning in the market for head and neck cancer treatment, projecting Bicara shares to outperform in the market. Stifel also maintained a Buy rating with a $47 target, noting that Bicara’s enterprise value presents an investment opportunity ahead of anticipated data disclosures.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.